Minimally invasive transperineal laser ablation (TPLA) of the prostate appears effective for benign prostatic hyperplasia (BPH), according to a review published online Sept. 21 in Therapeutic Advances ...
Daniel Su, MD, a urologist at Orange County Urology Associates (OCUA), has performed the first commercial Vanquish® Water Vapor Ablation procedures in the state of California, offering patients a new ...
Transurethral ablation of Gleason grade group 2 (GG2) lesions using water vapor therapy cleared the area of prostate cancer in 75% of men and 91% had no GG2 or higher-grade cancer remaining at 6 ...
TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA). Vanquish is a transurethral, ultrasound and ...
Francis’ ongoing VAPOR 2 single-arm study aims to support a 510(k) application for Vanquish at the FDA this July, with one-year data from 235 patients diagnosed with localized, intermediate-risk ...
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...
Use of the Prostatype P-score to predict adverse pathology (AP) at radical prostatectomy (RP). This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results